SimplicityBio SA

SimplicityBio’s vision is to provide partners and customers with robust biomarkers with biological and therapeutic significance. It helps biotech and medtech companies create robust signatures models by using a panel of biomarkers based on genomics, proteomics or metabolomics (‘omics’) data. These models can be used, for instance, to bring molecular diagnostic tests to market, or for patient stratification in order to develop more effective medicaments.

SimplicityBio is a spin-off from the University of Applied Sciences, Western Switzerland and was incubated at the BioArk in Monthey. The company was founded in 2015 by Miguel Barreto, a Ph.D. in Information Systems from Lausanne University who is an expert in machine learning and bioinformatics; Matthew Hall, a Ph.D. in Biology with advanced knowledge in NextGen Sequencing; and Pedro Faustino, EMBA a specialist in technology.